Orbimed Advisors LLC Rapt Therapeutics, Inc. Transaction History

Orbimed Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$11.28 - $25.46 $10.9 Million - $24.5 Million	-963,532 Reduced 77.4%	281,413 $6.99 Million
Q3 2023 Nov 14, 2023	SELL	$16.34 - $24.66 $100,082 - $151,042	-6,125 Reduced 0.49%	1,244,945 $20.7 Million
Q3 2022 Nov 14, 2022	BUY	$17.96 - $30.46 $6.91 Million - $11.7 Million	384,674 Added 44.4%	1,251,070 $30.1 Million
Q2 2022 Aug 15, 2022	BUY	$10.26 - $23.59 $5.18 Million - $11.9 Million	505,096 Added 139.8%	866,396 $15.8 Million
Q1 2022 May 16, 2022	BUY	$17.02 - $40.22 $2.46 Million - $5.8 Million	144,300 Added 66.5%	361,300 $7.95 Million
Q4 2021 Feb 14, 2022	BUY	$29.5 - $39.5 $6.4 Million - $8.57 Million	217,000 New	217,000 $7.97 Million

104

27.1M

26.7K

2.4K

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $26.1M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.